Syneos Health, Aetion form RWE collaboration
Partnership to focus on gains for clinical development and commercialization through patient data curation and real-world data
Syneos Health, a biopharma clinical and commercial solutions organization, and Aetion, a healthcare technology company that provides real-world evidence (RWE) for life sciences, payers, providers and regulatory agencies, have forged a partnership to deliver data and analytics-driven solutions that look to expand drug development and improve patient outcomes.
The collaboration combines Syneos Health’s proprietary data collection and research tools with the software company’s Aetion Evidence Platform (AEP) to generate evidence through patient data curation and real-world data.
Syneos Health’s offerings, the company says, allow biopharma companies to speed up product development and patient access to new therapies; lessen risk via evidence-based decision-making; and exhibit value to a broad healthcare ecosystem, including patients, regulators, payers, and healthcare providers. Aetion’s AEP analyzes data from the real world—such as claims, electronic health records, registries, and clinical trial data—to produce RWE on the safety, effectiveness, and value of medical interventions.
“Today’s dynamic healthcare landscape is challenging the product development process as regulatory authorities and payers demand faster and greater proof of value for therapies, and improved outcomes for patients,” notes Christian Tucat, president, Syneos One and RWE for Syneos Health. “Integrating Syneos Health and Aetion’s solutions drives quality, transparency, and speed in the use of patient-level data by leveraging Aetion’s strong analytics platform and capabilities. This places the patient closer to the center of research, unlocking efficiencies across development and commercialization, speeding patient access, and maximizing the return on investment for our customers.”
